New ECMOLife Publication Available!
FULL ARTICLE HERE: https://pubmed.ncbi.nlm.nih.gov/34496921/
A recent pilot study in 40 patients sustains the advantages of ECMOLife magnetic levitation pump on hemolysis risk reduction.
In this study, ECMOLife magnetic levitation pump was compared with Vortex centrifugal pump. The study group (ECMOLife) had significantly lower levels of plasma free hemoglobin (PFH) and lactate dehydrogenase (LDH) in the immediate postoperative period.
This is the first time a study comparing both technologies has hemolysis as an endpoint, proving the efficacy of the concept behind ECMOLife in clinical practice.
